Tulane Cancer Center | Strategic Alliance Partners

Latest from Tulane Cancer Center


Dr. Sartor on Provenge in Combination with Radium-223

April 01, 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.